MEI Pharma, Inc. (0JW9.L)

3,4450 -0,3265 (-8,66%) Alla chiusura: 06:22PM BST

MEI Pharma, Inc.

11455 El Camino Real
Suite 250
San Diego, CA 92130
United States
858 369 7100
https://www.meipharma.com

Settore/i: 
Settore: 
Impiegati a tempo pieno: 46

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Mr. David M. Urso B.A., Esq., J.D.	CEO, President & Director	748,46k	N/D	1964
Dr. Richard G. Ghalie M.D., MBA	Chief Medical Officer	627,76k	N/D	1958
Mr. Justin J. File	CFO & Corporate Secretary	N/D	N/D	1970
Ms. Yomara Gomez-Naiden	Senior Vice President of Operations & Quality	N/D	N/D	N/D
Ms. Nicole Chyoko Iida	Vice President of Legal Affairs	N/D	N/D	N/D
Ms. Anne Frese	Chief People Officer	N/D	N/D	N/D
Dr. Robert D. Mass	Strategic Advisor	201,68k	N/D	1954
Mr. David A. Walsey J.D., L.L.M.	Senior Vice President of Corporate Affairs	N/D	N/D	N/D

Gli importi risalgono al giorno 31 dicembre 2023 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

MEI Pharma, Inc., a clinical-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor for the treatment of patients with relapsed/refractory follicular lymphoma; and Voruciclib, an oral cyclin-dependent kinase 9 inhibitor, which is in Phase I clinical trial for acute myeloid leukemia and B-cell malignancies. It also develops ME-344, a mitochondrial inhibitor targeting the oxidative phosphorylation complex which has completed Phase I clinical trial for the treatment of human epidermal growth factor receptor 2 negative breast cancer. MEI Pharma, Inc. has a license agreement with Presage Biosciences, Inc. The company was formerly known as Marshall Edwards, Inc. and changed its name to MEI Pharma, Inc. in July 2012. MEI Pharma, Inc. was incorporated in 2000 and is headquartered in San Diego, California.

Governance aziendale

L'ISS Governance QualityScore di MEI Pharma, Inc. al N/D è N/D. I criteri di valutazione fondamentali sono revisione: N/D; Consiglio di Amministrazione: N/D; diritti degli azionisti: N/D; retribuzione: N/D.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.